Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

NCT05973903 is registered in ClinicalTrials.gov with Tel Aviv Medical Center as lead sponsor.

NCT NCT05973903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05973903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
Lead sponsor
Tel Aviv Medical Center
Phase
Phase 1/2
Overall status
Withdrawn
Start date
June 1, 2024
Completion date
October 1, 2027
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gbm